On the exploitation of serendipity in drug discovery by Baumeister, A.A. et al.
Baumeister et al., Clin Exp Pharmacol 2013, 3:3 
DOI: 10.4172/2161-1459.1000e121
Open AccessEditorial
Volume 3 • Issue 3 • 1000e121Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
On the Exploitation of Serendipity in Drug Discovery
Alan A Baumeister1, Joni Lee Pow1, Kristopher Henderson1 and Francisco López-Muñoz2,3*
1Department of Psychology, Louisiana State University, Baton Rouge, USA
2Faculty of Health Sciences, Camilo José Cela University, Madrid, Spain
3Department of Pharmacology, University of Alcalá, Madrid, Spain
*Corresponding author: Francisco López-Muñoz, Faculty of Health Sciences, 
Camilo José Cela University, C/ Castillo de Alarcón, 49, Urb. Villafranca del 
Castillo, 28692 Villanueva de la Cañada, Madrid, Spain, Tel: 34-91-815-3131; Fax: 
34-91-860-9343; E-mail: francisco.lopez.munoz@gmail.com
Received April 17, 2013; Accepted April 19, 2013; Published April 21, 2013
Citation: Baumeister AA, Pow JL, Henderson K, López-Muñoz F (2013) On 
the Exploitation of Serendipity in Drug Discovery. Clin Exp Pharmacol 3: e121. 
doi:10.4172/2161-1459.1000e121
Copyright: © 2013 Baumeister AA, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
We have written previously about the nature of serendipity and 
the role that it played in the “Psychopharmacology Revolution” of the 
1950s and 1960s [1-3]. However, we have not previously addressed the 
issue of whether it is possible or desirable to design studies to enhance 
and exploit serendipity. We do so here.
First, it is essential to establish a definition of serendipity. As we 
suggested previously [1], the term serendipity shall be defined as “the 
discovery of something not sought”. This definition, like most others, 
requires the element of sagacity. The observation of “something not 
sought” will not lead to discovery unless someone has the mental 
discernment (sagacity) required to recognize that the observation 
has significance. However, sagacity cannot be used to differentiate 
serendipitous from non-serendipitous discoveries because it is a 
necessary attribute of both. Sagacity and discovery are synonyms in 
this context.
Most definitions of serendipity require the element of chance. 
Indeed, discussions of serendipity invariably quote Pasteur’s famous 
dictum “Chance favors the prepared mind” [4]. Whether chance 
is a feature of serendipity depends on one’s definition of chance. A 
common definition of chance treats the word as a synonym for random. 
Thus, Dictionary.com defines chance as “the absence of any cause 
of events that can be predicted, understood, or controlled” [5]. The 
Free Dictionary defines chance as “The unknown and unpredictable 
element in happenings that seems to have no assignable cause” [6]. If 
this meaning of chance is a required element of serendipity then the 
construct of serendipity is rendered non-scientific, for certainly science 
can only explain events that have causes. Another way to define chance 
is “something that happens unpredictably without discernible human 
intention…” [7]. Here chance is treated as mere coincidence. There is 
nothing scientifically objectionable to this definition. However, when 
used in this way, chance is equivalent to the phrase “something not 
sought”.
Most experts in psychopharmacology would agree that, by 
comparison to the period referred to above as the “Psychopharmacology 
Revolution” [8], the pace of discovery of novel psycho-pharmaceuticals 
in recent years has been relatively anemic. It is critically important to 
identify factors that may now stifle drug development. At least one 
prominent expert has attributed the apparent stagnation to a decline in 
serendipity [9]. Indeed, many commentators, us included [1-3], have 
observed that serendipity played a pronounced role in the discoveries 
of the earlier period.
Several putative “anti-serendipity” factors that may interfere with 
current drug development have been identified. These include 1) 
movement toward rational drug design based on translational research, 
2) reduction in the amount of time that clinicians have to observe
patients, and 3) reliance on the double-blind placebo control design to
demonstrate efficacy [9].
The trend toward rational drug design is clear [10]. However, its 
relationship to serendipity is opaque. Rational drug design guided by 
translational research refers to the development of drugs deliberately 
designed to alter processes that have been implicated in mental 
pathology by basic research. Rational drug design, by its very nature, 
constricts the domain of drugs of interest by singling out for clinical 
trial only those compounds that basic research and theory suggest 
may alter the mechanisms of psychopathology. Modern techniques 
enable rapid development and screening of thousands of compounds 
designed for activity at specific molecular or cellular targets. In the past, 
selection of drugs for clinical trials was based primarily on coincidental 
or deliberate observations of drug effects on the behavior of animals 
or humans. Thus, in a sense, early drug development was rational too. 
The difference between then and now is that now drugs must pass 
through a molecular/cellular screen before they are selected for molar 
physiologic, behavioral or clinical trials. If there has been a constriction 
of serendipity due to rational drug development, the impact of the 
effect is exerted at the initial phases of drug development and it is 
due to homogenization of the physico-chemical properties of agents 
that pass through the screen, thereby reducing both the variability 
of the biological effects of these compounds and the probability that 
“something not sought” will occur and be recognized. Constriction of 
serendipity is not an inherent aspect of rational drug design. Rather 
it is the consequence of theory. Screening of drugs designed to test 
different theories of the pathogenesis of mental illness would broaden 
the variability of biological effects and enhance the probability that 
“something not sought” will occur.
Another putative “anti-serendipity” factor is a constriction in 
the amount of time that clinical researchers have to observe drug 
effects. Interestingly, this has been linked to the closing of long-term 
care mental hospitals (i.e., deinstitutionalization) [9]. Several points 
are relevant here. First, testing of drugs that target severe mental 
illness, such as antipsychotics, is still often done in a hospital setting 
(see, for examplehttp://www.accessdata.fda.gov/drugsatfda_docs/
nda/97/20639 _seroquel_toc.cfm). Second, long-term observation is 
not usually required to observe therapeutic effects. The efficacy of most 
psychiatric medications is demonstrable within a few weeks or less. 
Typical phase III clinical trials last for six to eight weeks and involve 
hundreds to thousands of participants [10]. Often rating scales are 
used to measure drugs effects. Reliance on rating scales, as a substitute 
for longitudinal clinical observation, has been suggested to be another 
“anti-serendipity” factor [9]. However, the most commonly used rating 
scale, the Brief Psychiatric Rating Scale (BPRS), samples a broad range 
of symptom categories including somatic concern, anxiety, depression, 
suicidality, guilt, hostility, elevated mood, grandiosity, suspiciousness, 
hallucinations, unusual thought contentment, bizarre behavior, self-
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neglect, disorientation, conceptual disorganization, blunted affect, 
emotional withdrawal, motor retardation, tension, uncooperativeness, 
excitement, distractibility, motor hyperactivity and mannerisms and 
posturing [11]. Indeed, the BPRS is not so brief. Thus, the duration of 
modern clinical trials and the breadth of symptoms examined appear 
to provide ample opportunity for the observation of “something not 
sought”.
Another putative “anti-serendipity” factor is the use of the double-
blind placebo control design [9]. The principal objection to this design 
is that the design does not allow for analysis of individual differences 
in drug response. This is accurate. Outcome is expressed as a group 
average, and idiosyncratic responses are relegated to the status of 
background “noise” or error. Behavioral psychologists have vociferously 
complained about this for more than half a century, advocating the use 
of single subject designs (n=1) as an adjunct group designs [12]. Use of 
such designs in psychopharmacology would be fruitful in identifying 
individual response markers. However, single subject designs are rarely 
used in clinical drug trials. No doubt, this is because drug developers 
are more interested in drugs that have more or less uniform effects 
across a large number (group) of subjects (and potential customers), 
than identifying idiosyncratic effects in individual (n=1) subjects. 
However, the group design, rather than being an “anti-serendipity” 
factor, actually increases the odds of producing “something not 
sought” because of the inherent variability between subjects within 
groups. Single subject design would not promote serendipity per se. 
Rather, it provides a means for exploiting serendipitous observations 
by enabling researchers to understand why drug effects vary across 
individuals within groups, and in doing so, it would probably help to 
reveal multiple pathologies that are at present lumped together under 
single diagnostic categories.
Our analysis suggests that the current lack of innovation is not due 
to suppression of serendipity. What, then, is? The current bureaucratic 
requirements that must be satisfied before a new drug can be brought 
to market cost about 80 to 100 million dollars and require, on average, 
ten years reaching fruition [10]. The high costs in time and money 
create tremendous pressure on drug companies to reduce the risk that 
a drug selected for development will not be approved. A pervasive 
strategy for enhancing success in drug development is to develop 
drugs that are similar to those already been approved and are clinically 
successful. The result has been the marketing of multiple drugs that 
are virtually equivalent in mechanism of action and efficacy. There 
is much greater financial incentive for the development of so called 
“me too” drugs than novel compounds. This is a primary obstacle to 
innovation. The constriction in the diversity of compounds selected 
for clinical trial that is inherent in this approach reduces the range 
of possible outcomes and reduces the probability of discovering 
something “not sought”. Nevertheless, the system is not fundamentally 
“anti-serendipity”. A drug company that observes an unexpected but 
clinically useful and profitable effect of a drug in the course of testing 
it for something else will not care whether the discovery was made by 
accident during intentional development of “me too” drugs. The drug 
will be developed for the use “not sought”. For example, the effect 
of Viagra® (sildenafil) on penile erection was discovered during the 
testing of phosphodiesterase inhibitors for treatment of angina [13].
It has recently been suggested that serendipity is a “proven 
method” of science and that research designed to promote serendipity 
would stimulate innovation in drug development [9]. In the discussion 
above, we suggest that the probability of a serendipitous observation is 
related to variability in compounds tested, end points measured, and 
the time allocated to observe effects. A plausible case can be made that 
there has been a constriction in the range of compounds tested. This is 
driven by two forces - rational drug design and risk adversity. Rational 
drug design is synonymous with theory driven research. Retreat from 
theory driven research in order to promote serendipity would be a 
scientific regression. It would represent a retreat toward irrationality 
and the trial and error approach of the past. Regarding the range of 
outcome variables measured and the time allocated to observed effects, 
it is debatable whether these variables have actually been constricted. 
We agree that the pace of discovery of more efficacious drugs for the 
treatment of mental disorders in recent years has been relative slow. 
However, we attribute this to powerful economic incentives that 
promote the development of drugs that have mechanisms of action 
similar to drugs already on the market. Enhancing serendipity is not the 
remedy for the stagnation of drug development. Rather, the solution 
lies in increased testing of novel theories and compounds. This solution 
is antithetical to the entrepreneurial, private-sector, profit-motive 
approach that drives most drug development. Herein lie an exemplary 
role for government-supported research aimed at testing novel theories 
and compounds without regard to the bottom line.
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